The antiinflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-β1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells

Autoimmunity

Volumn 32, Issue 4, 2000, Pages 265-270

  Nicoletti, F ^a   Di Marco, R ^a   Patti, F ^a   Nicoletti, A ^a   Leonardi, C ^a   Reggio, E ^a   Meroni, P ^a   Reggio, A ^a  

^a NONE   (Italy)

Author keywords

Cytokines; Interferon ; Interleukin 13; Multiple sclerosis

Indexed keywords

CYTOKINE; INTERFERON BETA SERINE; INTERLEUKIN 13;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CIRCULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS;

EID: 0034520544     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916930008994100     Document Type: Article

References (28)

1. Critical influences of the cytokine orchestration on the outcome of myelin-antigen specific T cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis
2. Th and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases
3. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus
4. Cytokines and natural regulator of cytokines
5. Immunological mechanisms and therapy in multiple sclerosis
6. Multiple sclerosis: A unique immunopathological syndrome of the central nervous system
7. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis
8. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
9. Tumor necrosis factor-α messanger RNA expression in patients with relapsing remitting multiple sclerosis is associated with disease activity
10. Circulating levels of IL-1 ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-β treatment
11. Blood levels of transforming growth factor-beta 1 (TGF-β1) are elevated in both relapsing remitting and chronic progressive multiple scelrosis (MS) patients and are further augmented by treated with interferon-beta-1b (IFN-β-1b)
12. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis
13. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease
14. Interferon-beta in multiple sclerosis
15. The role of IL-13 and its receptor in allergy and inflammatory responses
16. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
17. Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients
18. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes
19. In vivo suppression of NF-kB and preservation of IkBα by interleukin-10 and interleukin-13
20. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia. Correlation with down-modulation of TNF-α, IFN-γ and IL-12 production
21. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13
22. Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence
23. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
24. Protective effects of IL-4, IL-10, IL-12 and IL-13 in IgG immune complex-induced lung injury. Role of endogenous IL-12
25. Interleukin-13 prevents autoimmune diabetes in NOD mice
26. Macrophage-inactivating IL-3 suppresses experimental autoimmune encephalomyelitis in rats
27. Interferon-beta induces interleukin-10 expression: Relevance to multiple sclerosis
28. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis